A combination immunotherapy treatment of nivolumab plus ipilimumab was associated with no improvement in survival for advanced cancers other than melanoma, when compared to nivolumab alone, according to a recent Northwestern ...
Sep 22, 2023
0
59
Dabrafenib plus trametinib results in significantly more responses and longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations, according to a study ...
Sep 21, 2023
0
16
The immunotherapy agent atezolizumab induces sustained responses in about one-third of patients with advanced alveolar soft part sarcoma (ASPS), according to a study published in the Sept. 7 issue of the New England Journal ...
Sep 8, 2023
0
26
The Alliance for Clinical Trials in Oncology today announced that an independent Data and Safety Monitoring Board (DSMB) determined that the phase III CABINET (A021602) pivotal trial met its primary endpoint at an interim ...
Aug 24, 2023
0
19
A research team co-led by UCLA investigators has shown that an immunotherapy drug combination can be an effective second-line therapy for patients with an aggressive and deadly type of melanoma that is resistant to the widely ...
Aug 17, 2023
0
38
As medical technology advances, many diseases could be detected, prevented and cured with cells, rather than pills.
Aug 13, 2023
0
55
Thanks to machine learning algorithms, short pieces of DNA floating in the bloodstream of cancer patients can help doctors diagnose specific types of cancer and choose the most effective treatment for a patient.
Aug 2, 2023
0
21
Aging is closely related to redox stress. The free radical theory of aging believes that free radicals cause aging by oxidative damage to macromolecules. However, the clinical application of antioxidants to anti-aging is ...
Jun 21, 2023
0
11
Celiac disease is a chronic disease that can't be cured, but treatment can help with symptoms.
Jun 15, 2023
1
10
Among patients with extensive stage small-cell lung cancer (SCLC) that is positive for expression of the Schlafen-11 gene (SLFN11), those who received maintenance atezolizumab immunotherapy plus the PARP inhibitor talazoparib ...
Jun 5, 2023
0
2
